p53: Functions, mutations and sarcomas

Acta Orthopaedica Scandinavica, Supplement

Volumn 68, Issue 273, 1997, Pages 68-73

  Hung, Jaclyn ^a   Anderson, Robin ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CANCER GENETICS; FAMILIAL CANCER; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MOUSE; NONHUMAN; OSTEOSARCOMA; REVIEW; SOFT TISSUE SARCOMA; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; ANIMAL; CHEMICAL STRUCTURE; GENETICS; MUTATION; POINT MUTATION; REGULATOR GENE; SARCOMA; SOFT TISSUE TUMOR;

ANIMALS; GENES, P53; GENES, REGULATOR; GERM-LINE MUTATION; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; OSTEOSARCOMA; POINT MUTATION; SARCOMA; SARCOMA, EXPERIMENTAL; SOFT TISSUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031066194     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Birch J, Hartley A, Tricker K, et al. (1994). Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni Families. Cancer Res 54: 1298-1304.
2. Brugarolos J, Chandrasekaran C, Gordon JI, et al. (1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-7.
3. Chang F, Syrjanen S, Tervahauta A, Syrjanen K (1993). Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68: 653-661.
4. Cho Y, Gorina S, Jeffrey PD, Pavletic NP (1994). Crystal Structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations [see comments]. Science 265: 346-55.
5. Cross SM, Sanchez CA, Morgan CA, et al. (1995). A p53 dependent mouse spindle checkpoint. Science 267: 1353-6.
6. Ditter D, Pati S, Zambetti G, et al. (1993). Gain of functions mutations in p53. Nature Genetics 4: 42-5.
7. Donehower LA, Harvey M, Slagle BL, et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-21.
8. Dutta A, Ruppert SM, Aster JC, Winchester E (1993). Inhibition of DNA replication factor RPA by p53. Nature 365: 79-82.
9. Eeles RA (1995). Germline Mutations in the TP53 Gene. Cancer Surveys 25: 101-24.
10. Eliyahu D, Michalovitz D, Eliyahu S, et al. (1989). Wildtype p53 can inhibit oncogene-mediated focus formation. Proceedings of the National Academy of Sciences of the USA 86: 8763-67.
11. Finlay CA, Hinds PW, Levine AJ (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-93.
12. Folkman J (1992). The role of angiogenesis in tumor growth. Seminar in Cancer Biology 3: 65-71.
13. Fraumeni JFJ (1996). An interdisciplinary approach to populations at high risk of cancer - Charles S. Molt Prize. Cancer 178: 548-52.
14. Graeber TG, Osmanian C, Jacks T, et al. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
15. Guillouf C, Rosselli F, Krishnaraju K, et al. (1995). p53 involvement in control of G2 exit of cell cycle: role in DNA damage-induced apoptosis. Oncogene 10: 2263-70.
16. Hann BC, Lane DP (1995). The dominating effect of mutant p53. Nature Genetics 9: 221-2.
17. Harvey M, Mcarthur MJ, Montgomery Jr CA, et al. (1993). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB 7: 938-43.
18. Harvey M, Vogel H, Morris D, et al. (1995). A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genetics 9: 305-11.
19. Hinds P, Finlay C, Levine AJ (1989). Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63, 739-46.
20. Hollstein M, Rice K, Greenblatt MS, et al. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551-3555.
21. Iwabuchi K, Li B, Bartel P, Fields S (1993). Use of the 2-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene 8: 1693-6.
22. Jenkins JR, Rudge K, Currie GA (1984). Cellular immortalisation by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312: 651-4.
23. Kastan MB, Zhan Q, El-Deiry WS, et al. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-97.
24. Kastan MB, Canman CE, Leonard CJ (1995). P53, cell cycle control and apoptosis: implications for cancer. [Review]. Cancer Metastasis Rev 1995; 14: 3-15.
25. Kieser A, Weich HA, Brander G, et al. (1994). Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-9.
26. Kinzler KW, Vogelstein B (1996). Life (and death) in a malignant tumour. Nature 379: 19-20.
27. Knudson AGJ (1971). Mutations and Cancer. Proceedings of the National Academy of Sciences of the USA 68: 820-3.
28. Knudson AGJ (1989). Hereditary cancers discloses a class of cancer genes. Cancer Res 63: 1888-91.
29. Knudson AGJ (1993). All in the (cancer) family. Nature Genetics 5: 103-4.
30. Ko LJ, Prives C (1996). p53: puzzle and paradigm. Genes & Development 10: 1054-72.
31. Lane DP (1992). Cancer p53, guardian of the genome [news; comment]. Nature 358: 15-6.
32. Lane DP (1994a). p53 and human cancers. Br Med Bull 50: 582-99.
33. Lane DP (1994b). The regulation of p53 function: Steiner Award Lecture. Int J Cancer 57: 623-7.
34. Lane DP, Crawford LV (1979). T antigen is bound to a host protein in SV40 transformed cells. Nature 278: 261-3.
35. Lavigueur A, Maltby V, Mock, et al. (1989). High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9: 3982-91.
36. Law JC, Strong LC, Chidambaram A, Ferrell RE (1991). Germline mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res 51: 3551-5.
37. Leach FS, Tokino T, Meltzer P, et al. (1993). p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-4.
38. Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature 351: 453-6.
39. Li FP (1996). Hereditary cancer Susceptibility - Charles S. Mott Prize. Cancer 78, 553-7.
40. Li F, Garber J, Friend S, Strong L, et al. (1992). Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 1992; 84: 1156.
41. Li R, Botchan MR (1993). The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell 73: 1207-21.
42. Lin J, Teresky AK, Levine A (1995). Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10: 2387-90.
43. Linzer DIH, Levine AJ (1979). Characterization of a 54 000 MW cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-53.
44. Malkin D, Jolly K, Barbier N, et al. (1992). Germline mutations of the p53 tumor suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326: 1309-15.
45. Malkin D, Li F, Strong L, et al. (1990). Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
46. McBride OW, Merry D, Givol D (I986). The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proceedings of the National Academy of Sciences of the USA 83: 130-4.
47. Miller C, Mohandas T, Wolf D, et al. (1986). Human p53 localized to short arm of chromosome 17. Nature 319: 783-4.
48. Miller CW, Aslo A, Tsay C, et al. (1990). Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 1990; 50: 7950-4.
49. Momand J, Zambetti GP, Olson DC, et al. (1992). The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-45.
50. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK (1990). Mechanisms of p53 loss in human sarcomas. Proceedings of the National Academy of Sciences of the USA 87: 5863-7.
51. Oliner JD, Kinzler KW, Meltzer PS, et al. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas [see comments]. Nature 358: 80-3.
52. Oliner JD, Pietenpol JA, Thiagalingam S, et al. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-60.
53. Parada LF, Land H, Weinberg RA, Wolf D, Rotter W (1984). Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312: 649-51.
54. Pollock RE, Lang AQ, Luo JX, et al. (1996). Soft tisssue sarcoma metastasis from clonal expansion of p53 mutated tumour cells. Oncogene 12: 2035-9.
55. Reich NC, Oren M, Levine AJ (1983). Two distinct mechanisms regulate the levels of cellular tumor antigen, p53. Mol Cell Biol 1983; 3: 2143-50.
56. Rogel A, Popliker M, Webb CG, Oren M (1985). p53 cellular tumor antigen: analysis of mRNA levels in normal and adult tissues, embryos and tumors. Mol Cell Biol 5: 2851-5.
57. Santibanez-Koref M, Birch J, Harley A, et al. (1991). p53 germline mutation in Li-Fraumeni syndrome. Lancet 338: 1490-91
58. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V (1990). Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tmorigenesis. Mol Cell Biol 10: 6565-77.
59. Soussi T, de Fromentel C, May P (1990). Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 935-52.
60. Srivastava S, Zou Z, Pirollo K, et al. (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-9.
61. Unger T, Nau MM, Segal S, et al. (1992). p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO Journal 1992; 11: 1383.
62. Vogelstein B, Kinzler KW (1992). p53 function and dysfunction. Cell 70: 523-6.
63. Vogelstein B, Kinzler KW (1994). X-rays strike p53 again. Nature 370: 174-5.
64. Wu X, Bayle H, Olson D, Levine AJ (1993). The p53-mdm-2 autoregulatory feedback loop. Genes & Development 7: 1126-32.
65. Yamaguchi T, Toguchida J, Yamamuro T.et al. (1992). Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 52: 2419-23.